{"transactions":[{"id":768739,"issuer":{"id":2118,"kind":"organization","name":"QUEST DIAGNOSTICS INC","symbol":"DGX"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T20:57:33.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":1142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted stock units."}],"balance_after":5196,"source":{"system":"sec-edgar","filing":"0001720081-26-000002","document":"wk-form4_1779397051.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1022079/000172008126000002/wk-form4_1779397051.xml","form_type":"4"}},{"id":1143663,"issuer":{"id":2118,"kind":"organization","name":"QUEST DIAGNOSTICS INC","symbol":"DGX"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T20:24:09.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":1203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted stock units."}],"balance_after":4054,"source":{"system":"sec-edgar","filing":"0001022079-25-000149","document":"wk-form4_1747686237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207925000149/wk-form4_1747686237.xml","form_type":"4"}},{"id":1509565,"issuer":{"id":2118,"kind":"organization","name":"QUEST DIAGNOSTICS INC","symbol":"DGX"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-20T23:13:49.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":1482,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted share units."}],"balance_after":2851,"source":{"system":"sec-edgar","filing":"0001022079-24-000113","document":"wk-form4_1716246819.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207924000113/wk-form4_1716246819.xml","form_type":"4"}},{"id":1885565,"issuer":{"id":2118,"kind":"organization","name":"QUEST DIAGNOSTICS INC","symbol":"DGX"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-19T22:25:18.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":1369,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted share units."}],"balance_after":1369,"source":{"system":"sec-edgar","filing":"0001022079-23-000118","document":"wk-form4_1684535101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207923000118/wk-form4_1684535101.xml","form_type":"4"}},{"id":1904410,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:08.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":2.8,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001640455-23-000106","document":"wf-form4_168320057476652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000106/wf-form4_168320057476652.xml","form_type":"4"}},{"id":1904409,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:08.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":7.27,"underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-23-000106","document":"wf-form4_168320057476652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000106/wf-form4_168320057476652.xml","form_type":"4"}},{"id":1904408,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:08.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":7.58,"underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-23-000106","document":"wf-form4_168320057476652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000106/wf-form4_168320057476652.xml","form_type":"4"}},{"id":1904407,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:08.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":4.46,"underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-23-000106","document":"wf-form4_168320057476652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000106/wf-form4_168320057476652.xml","form_type":"4"}},{"id":1904406,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:08.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10163,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":7.92,"underlying":"Common Stock","underlying_shares":10163},"source":{"system":"sec-edgar","filing":"0001640455-23-000106","document":"wf-form4_168320057476652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000106/wf-form4_168320057476652.xml","form_type":"4"}},{"id":1904405,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:08.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent (\"Merger Sub\"), dated as of March 26, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 3, 2023 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":14.78,"underlying":"Common Stock","underlying_shares":27100},"source":{"system":"sec-edgar","filing":"0001640455-23-000106","document":"wf-form4_168320057476652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000106/wf-form4_168320057476652.xml","form_type":"4"}},{"id":2220128,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-28T21:00:34.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2023 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":20000,"derivative":{"exercise_price":2.8,"expiration_date":"2032-06-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001640455-22-000068","document":"wf-form4_165646441517959.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045522000068/wf-form4_165646441517959.xml","form_type":"4"}},{"id":2658794,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-22T16:44:18.000Z","date":"2021-06-18","kind":"grant","acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2022 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":15700,"derivative":{"exercise_price":7.27,"expiration_date":"2031-06-18","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-21-000109","document":"wf-form4_162439461873408.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000109/wf-form4_162439461873408.xml","form_type":"4"}},{"id":3091888,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T19:28:11.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 filed on June 29, 2020 erroneously reported 13,550 shares of common stock subject to the stock option. This amendment is being filed to disclose the correct number of shares subject to the reported stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":15700,"derivative":{"exercise_price":7.58,"expiration_date":"2030-06-26","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-20-000084","document":"wf-form4a_159373245809682.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000084/wf-form4a_159373245809682.xml","form_type":"4/A","original_submission_date":"2020-06-29"}},{"id":3097554,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-29T19:28:33.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":13550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":13550,"derivative":{"exercise_price":7.58,"expiration_date":"2030-06-26","underlying":"Common Stock","underlying_shares":13550},"source":{"system":"sec-edgar","filing":"0001640455-20-000068","document":"wf-form4_159347329773858.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000068/wf-form4_159347329773858.xml","form_type":"4"}},{"id":3491394,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-13T10:32:38.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2020 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":15700,"derivative":{"exercise_price":4.46,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-19-000059","document":"wf-form4_156043633809821.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045519000059/wf-form4_156043633809821.xml","form_type":"4"}},{"id":3886139,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-21T17:14:39.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":10163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":10163,"derivative":{"exercise_price":7.92,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":10163},"source":{"system":"sec-edgar","filing":"0001640455-18-000082","document":"wf-form4_152961566234908.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000082/wf-form4_152961566234908.xml","form_type":"4"}},{"id":4181884,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":45409,"kind":"person","name":"Diaz Luis","position":1,"cik":"0001720081","reported_name":"Diaz Luis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-10-23T08:29:16.000Z","date":"2017-10-20","kind":"grant","acquired":true,"shares":27100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on October 20, 2017 and will vest in equal quarterly installments during the twelve quarters following the grant date."}],"balance_after":27100,"derivative":{"exercise_price":14.78,"expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":27100},"source":{"system":"sec-edgar","filing":"0001720081-17-000007","document":"wf-form4_150876174291404.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000172008117000007/wf-form4_150876174291404.xml","form_type":"4"}}]}